Financial Shenanigans

Financial Shenanigans - Repro India Limited (REPRO)

Figures converted from INR at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

1. The Forensic Verdict

Risk grade: Elevated (58 / 100). REPRO is not a fraud story, but it is a story where multiple linked warning signs have surfaced in the same six-month window. The Mahape plant — flagged in the FY2025 statutory audit as a Key Audit Matter for impairment, inventory valuation and employee-dues provisioning — has now spawned two consecutive quarters of one-time charges ($2.0M in Sep-25, $2.0M "exceptional" in Dec-25), an ICRA outlook downgrade to Negative on the $18.0M debt facility (Apr-26), an Independent Director resignation citing "personal reasons" (Bhumika Batra, Feb-26) and a publicly noted reconciliation gap between disclosed exceptional items and reported PBT/PAT. The auditor (M S K A & Associates, a BDO India member firm) has issued an unmodified opinion and there is no restatement, regulatory action or auditor resignation, which keeps the grade out of "High". The single data point that would most change the grade is a clean reconciliation of the Dec-25 exceptional item to PBT/PAT in the FY2026 audited accounts — without it, the grade tightens.

Shenanigans scorecard - all 13 categories

2. Breeding Ground

The breeding-ground score is moderate-amplifying: a founding-family controlled business with four executive Vohra-family directors out of an eight-person board, two recent independent-director seat changes, and one independent director who has just resigned in the same news cycle as the accounting query. Auditor tenure resets in FY26 (re-appointment for another 5-year term), credit rating outlook has just gone Negative, and management commentary in MD&A is unusually loose for a regulated filing. There is no compensation-driven incentive to inflate (no large stock-comp programme; promoters take statutory remuneration), but the structural conditions to dampen aggressive accounting choices are weaker than in non-promoter Indian peers.

The single 3.6 pp drop in promoter holding between Jun-23 and Sep-23 corresponds with FII entry rising from 6.3% to 10.2% — the most likely explanation is a placement / promoter dilution rather than open-market sale, but the underlying SAST/PIT filings should confirm.

3. Earnings Quality

Earnings quality is mixed. The income statement is small ($54.5M revenue, ~zero net profit in FY25), so even modest below-the-line items dominate. The recurring concern is that "other income" and "exceptional items" have repeatedly been the swing factor between profit and loss, while a non-trivial slice of operating cost is being capitalised to assets that have not yet generated cash.

In FY2018, $4.3M of "other income" turned a $2.1M operating profit into $2.5M net income — that one-line gain made the difference between barely-profitable and visibly profitable. In FY2023 and FY2024, headline net profit was already small ($1.1M, $1.4M); a single negative quarter is enough to flip the sign, which is exactly what happened in FY25. The right way to think about REPRO's earnings is therefore operating profit ± exceptional items, not the net-profit headline.

The Sep-25 quarter (Q2 FY26) shows operating profit of $0.85M against negative "other income" of $2.0M, producing the $2.3M net loss. The Dec-25 quarter then carries a separate $2.0M "exceptional expense" line. Both items relate to the Mahape plant (long-idle, since approximately 2017-18 per the news report describing the property as having been "idle for eight years"). The auditor's FY25 Key Audit Matter explicitly references "labour strike and closure of Mahape plant" with audit work focused on impairment of property, plant and equipment, inventory valuation and employee-dues provision. That sequencing — the audit identifies the issue, then two consecutive quarters book ~$4M of charges, then the property is sold for $30.1M — is internally consistent, but the timing of the impairment recognition is the classic earnings-management lever and deserves underwriting.

Capitalisation of operating cost

Per the FY25 statutory audit, cumulative ~$5.8M has been capitalised to the technology project across FY24-FY25 (capex + new intangibles + CWIP), against an MD&A disclosure that the digital initiative is "not fully commercially operational". This is the single highest-confidence "shifting current expenses to later periods" finding. The amortisation policy and the test for impairment trigger when revenue from the segment falls short are the two disclosures to read in the FY26 audited accounts.

Tax line

A multi-year run of negative effective tax rates (FY2017 through FY2023) reflects deferred-tax-asset recognition / tax credits offsetting modest pre-tax losses or profits, then the rate jumps to 36% in FY25 on a near-zero base. This is sector-normal volatility for a small Indian company, but it is also a small-but-recurring tool for managing reported net profit when the headline number is close to zero.

4. Cash Flow Quality

Cash-flow quality is passable but cosmetically helped by capex/working-capital timing. The 5-year sum of CFO is $21.1M, which is real cash the operating business produced. But CFO has been consumed almost entirely by investing outflows ($18.0M over 5 years; $8.3M in FY25 alone), and the resulting free cash flow has turned negative in FY24 and FY25.

Three observations:

1. Free cash flow (CFO minus investing outflow) is negative $4.3M over FY23-FY25 despite positive CFO. The borrowings line confirms it: gross debt rose from $5.9M at end-FY24 to $11.6M at end-FY25 to $14.3M at end-Sep-25 — a 159% increase in fifteen months that exactly matches what reported FCF says is happening. There is no cosmetic CFO inflation here; the cash-flow statement is telling the truth, but the company is funding capex and the Mahape wind-down with debt.
2. No supplier-finance or factoring red flag is disclosed, and the cash-flow statement matches the change in debt and cash on the balance sheet. CFO is small but believable.
3. The Mahape sale ($30.1M) will land in FY27 financing/investing. It will not show up as recurring cash generation; underwrite the FY27 cash-flow statement assuming a one-time investing inflow followed by debt paydown.

Working-capital contribution to CFO

Debtor days have compressed from 211 (FY21, COVID disruption) to 48 (FY25). This is the single biggest working-capital improvement in the file and largely explains how CFO has held up. There is no evidence of factoring, recourse-receivable sales, or bill-and-hold to inflate this number. Inventory days, however, drifted up from 65 to 73 in FY25 — small in absolute terms (~$0.6M) but moving the wrong way as revenue declined; the FY25 audit also noted "valuation of inventories" at the Mahape plant as part of the KAM, so a portion of finished goods may be carrying impairment risk.

5. Metric Hygiene

Metric hygiene is below average but not pathological. The MD&A in the FY25 Annual Report contains arithmetic that does not reconcile internally, which suggests editorial sloppiness rather than active manipulation, but it is the kind of disclosure quality that an institutional reader should not trust without a calculator.

The FY25 MD&A "Significant Change of Key Financial Ratios" section reports a debt-equity ratio change of 147% as if the number itself is the headline. The actual headline is in the underlying line: bank borrowings doubled in twelve months, then rose another 28% in the following six months, while operating profit fell ~40%. That is the real metric story, and the ratio table buries it.

6. What to Underwrite Next

The accounting risk at REPRO today is at the valuation-haircut to position-sizing-limiter end of the spectrum, not a thesis breaker. Five questions, in priority order, will move the grade in either direction over the next two reporting cycles.

1. FY26 audited accounts: clean reconciliation of the $2.0M Q3 exceptional item to PBT/PAT. This is the single largest unresolved disclosure question. A clean note that maps the exceptional item line-by-line into pre-tax loss reduces the grade by 8-10 points. A repeat of the unreconciled gap raises it.
2. Mahape disposal accounting in FY27. Read the PPE note, the related impairment/reversal entries, and the gain/loss disposition. Specifically: was the carrying value already impaired (Sep-25 + Dec-25 charges of ~$4M), or is more impairment booked in FY26 to bridge to the $30.1M sale price? Underwrite earnings ex-disposal; do not let the gain on sale enter your run-rate operating earnings model.
3. Technology project: amortisation start date and impairment-trigger disclosure. Cumulative ~$5.8M capitalised across capex + intangibles + CWIP; MD&A still says the digital business is "not fully commercially operational". The FY26 amortisation expense and any impairment review under Ind AS 36 will tell you whether this is investment or expense-deferral.
4. ICRA outlook trajectory. The 29-Apr-2026 outlook revision to Negative on the $18.0M facility is the credit market's first formal warning. A further notch downgrade would be a thesis breaker; a return to Stable would significantly de-risk the file.
5. Independent director composition. With Batra resigned (Feb-26), Asher freshly appointed (Jul-25), Ghosh and Krishnan with less than two years of tenure, the audit committee depth has thinned. Watch for any further independent exits.